Get the Stockscreener App
1.015
0.49%
-0.005
After Hours:
1.01
-0.005
-0.49%
Zura Bio Ltd stock is traded at $1.015, with a volume of 200.15K.
It is down -0.49% in the last 24 hours and down -34.09% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
200.15K
Relative Volume:
0.52
Market Cap:
$62.81M
Revenue:
-
Net Income/Loss:
$-60.36M
P/E Ratio:
-0.231
EPS:
-4.394
Net Cash Flow:
$-15.05M
1W Performance:
-0.49%
1M Performance:
-34.09%
6M Performance:
-66.72%
1Y Performance:
-81.10%
1-Day Range:
$0.99
$1.04
1-Week Range:
$0.988
$1.07
52-Week Range:
$0.97
$5.50
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.015 | 64.35M | 0 | -60.36M | -15.05M | -4.394 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Northern Trust Corp Has $1.01 Million Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts - Defense World
Zura Bio shareholders approve board nominees and auditor - Investing.com Australia
Zura Bio shareholders approve board nominees and auditor By Investing.com - Investing.com Nigeria
Q1 Earnings Forecast for Zura Bio Issued By HC Wainwright - Defense World
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment - Investing.com Australia
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment By Investing.com - Investing.com India
Zura Bio (ZURA) Initiates Phase 2 Study for Tibulizumab in HS Treatment | ZURA Stock News - GuruFocus
Cubist Systematic Strategies LLC Makes New $62,000 Investment in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa - Quantisnow
Dimensional Fund Advisors LP Acquires New Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Wells Fargo & Company MN Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Barclays PLC Boosts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Raymond James Financial Inc. Invests $371,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $17.00 - Defense World
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheime - GuruFocus
ZURA: Oppenheimer Revises Price Target Amid Ongoing Trials | ZUR - GuruFocus
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheimer | ZURA Stock News - GuruFocus
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance
Ratio Analysis: Unpacking Zura Bio Ltd (ZURA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Zura Bio Ltd Inc. (ZURA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Do investors need to be concerned about Zura Bio Ltd (ZURA)? - uspostnews.com
Geode Capital Management LLC Increases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Yahoo
ZURA overperforms with a 8.76 increase in share price - uspostnews.com
Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Average Price Target from Analysts - Defense World
HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings - Defense World
HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00 - Defense World
ZURA stock touches 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating - Investing.com Australia
ZURA stock touches 52-week low at $1.07 amid market challenges - Investing.com
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating By Investing.com - Investing.com South Africa
Insiders' US$1.01m Investments In Red Following Zura Bio's US$21m Dip In Market Value - simplywall.st
Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio - Defense World
Zura Bio (NASDAQ:ZURA) Price Target Lowered to $10.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Chardan cuts Zura Bio stock target to $10, keeps buy rating By Investing.com - Investing.com South Africa
Chardan cuts Zura Bio stock target to $10, keeps buy rating - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target By Investing.com - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target - Investing.com
Leerink maintains $12 target on Zura Bio stock post-earnings By Investing.com - Investing.com Australia
Leerink maintains $12 target on Zura Bio stock post-earnings - Investing.com
Zura Bio Ltd expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Consensus Price Target from Analysts - Defense World
Rhumbline Advisers Has $94,000 Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
(Bi-)specific gravity: Bambusa, others serious about approach - BioWorld MedTech
Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Can Zura Bio's Novel Dual-Pathway Antibodies Transform Autoimmune Treatment? Key Updates Coming - Stock Titan
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80 - Defense World
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zura Bio Ltd Stock (ZURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thiara Parvinder | Director |
Sep 11 '24 |
Sale |
2.70 |
3,800,000 |
10,260,000 |
1,001,633 |
| Sidhu Someit | Director |
Sep 04 '24 |
Sale |
3.87 |
51,728 |
200,187 |
2,085,418 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):